These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. Ramdas V; Talwar R; Banerjee M; Joshi AA; Das AK; Walke DS; Borhade P; Dhayagude U; Loriya R; Gote G; Bommakanti A; Sivaram A; Agarwal G; Goswami A; Nigade P; Mehta M; Patil V; Modi D; Kumar H; Mallurwar S; Dash A; Modi F; Kuldharan S; Srivastava P; Singh M; Narasimham L; Gundu J; Sharma S; Kamboj RK; Palle VP J Med Chem; 2019 Dec; 62(23):10563-10582. PubMed ID: 31710479 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors. Boucle S; Tao S; Amblard F; Stanton RA; Nettles JH; Li C; McBrayer TR; Whitaker T; Coats SJ; Schinazi RF Bioorg Med Chem Lett; 2015 Sep; 25(17):3711-5. PubMed ID: 26099532 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones. Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732 [TBL] [Abstract][Full Text] [Related]
13. In Silico Approaches to the Design of NS5A Inhibitors. Ivanenkov YA; Veselov MS; Aladinskiy VA; Shakhbazyan AG; Yartseva SM; Majouga AG; Aladinskaya AV; Vantskul AS; Leonov SV; Ivachtchenko AV; Koteliansky VE Curr Top Med Chem; 2016; 16(12):1383-91. PubMed ID: 26585932 [TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry. Ahmed M; Pal A; Houghton M; Barakat K ACS Infect Dis; 2016 Nov; 2(11):872-881. PubMed ID: 27933783 [TBL] [Abstract][Full Text] [Related]
15. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595 [TBL] [Abstract][Full Text] [Related]
17. The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1. Tran TD; Wakenhut F; Pickford C; Shaw S; Westby M; Smith-Burchnell C; Watson L; Paradowski M; Milbank J; Brimage RA; Halstead R; Glen R; Wilson CP; Adam F; Hay D; Chiva JY; Nichols C; Blakemore DC; Gardner I; Dayal S; Pike A; Webster R; Pryde DC ChemMedChem; 2014 Jul; 9(7):1378-86. PubMed ID: 24729513 [TBL] [Abstract][Full Text] [Related]
18. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320 [TBL] [Abstract][Full Text] [Related]
19. Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors. Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L Bioorg Med Chem Lett; 2014 Dec; 24(24):5731-5737. PubMed ID: 25453810 [TBL] [Abstract][Full Text] [Related]
20. Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]